Bristol Myers Squibb (NYSE:BMY) Downgraded by Zacks Research to Hold

Posted by George Bondi on Oct 24th, 2026

Zacks Research downgraded shares of Bristol Myers Squibb (NYSE:BMY – Free Report) from a strong-buy rating to a hold rating in a research report report published on Thursday morning,Zacks reports.

Several other research firms have also recently issued reports on BMY. Morgan Stanley restated an “underweight” rating and set a $41.00 target price (up from $40.00) on shares of Bristol Myers Squibb in a research note on Wednesday, October 7th. Wells Fargo & Company reduced their price target on shares of Bristol Myers Squibb from $65.00 to $60.00 and set an “equal weight” rating for the company in a research note on Tuesday, October 13th. William Blair reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, October 12th. Royal Bank Of Canada restated a “sector perform” rating on shares of Bristol Myers Squibb in a research report on Monday. Finally, Daiwa Securities Group raised their target price on shares of Bristol Myers Squibb from $53.00 to $66.00 and gave the stock a “neutral” rating in a report on Tuesday, August 4th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $64.88.

View Our Latest Analysis on BMY

Bristol Myers Squibb Stock Down 2.3%

BMY stock opened at $61.58 on Thursday. The stock has a market capitalization of $125.79 billion, a P/E ratio of 13.56, a P/E/G ratio of 0.32 and a beta of 0.19. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. Bristol Myers Squibb has a 1-year low of $42.52 and a 1-year high of $68.64. The business has a fifty day moving average price of $63.26 and a 200-day moving average price of $60.33.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%. The company had revenue of $12.97 billion for the quarter, compared to analysts’ expectations of $11.74 billion. During the same period last year, the firm posted $1.46 earnings per share. Bristol Myers Squibb’s revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities analysts forecast that Bristol Myers Squibb will post 6.56 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio is presently 55.51%.

Insider Buying and Selling at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This represents a 2.88% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.05% of the stock is owned by company insiders.

Institutional Trading of Bristol Myers Squibb

Several large investors have recently added to or reduced their stakes in BMY. Altura Wealth Advisors Inc. raised its holdings in Bristol Myers Squibb by 1.2% during the third quarter. Altura Wealth Advisors Inc. now owns 13,717 shares of the biopharmaceutical company’s stock valued at $856,000 after acquiring an additional 161 shares during the period. Capital City Trust Co. FL lifted its position in shares of Bristol Myers Squibb by 0.7% in the third quarter. Capital City Trust Co. FL now owns 23,321 shares of the biopharmaceutical company’s stock valued at $1,455,000 after acquiring an additional 167 shares in the last quarter. Eagle Bay Advisors LLC lifted its position in shares of Bristol Myers Squibb by 2.6% in the third quarter. Eagle Bay Advisors LLC now owns 6,536 shares of the biopharmaceutical company’s stock valued at $408,000 after acquiring an additional 168 shares in the last quarter. Boltwood Capital Management boosted its stake in shares of Bristol Myers Squibb by 2.5% in the third quarter. Boltwood Capital Management now owns 7,107 shares of the biopharmaceutical company’s stock worth $443,000 after acquiring an additional 170 shares during the period. Finally, Sandy Cove Advisors LLC boosted its stake in shares of Bristol Myers Squibb by 4.7% in the second quarter. Sandy Cove Advisors LLC now owns 3,932 shares of the biopharmaceutical company’s stock worth $227,000 after acquiring an additional 176 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: Bristol Myers and SystImmune reported that izalontamab brengitecan reduced the risk of disease progression or death by 59% versus chemotherapy in the Phase 3 PANKU-Breast01 trial for advanced HR-positive/HER2-negative breast cancer. The result could strengthen BMY’s oncology pipeline and support a future regulatory filing. Bristol Myers, SystImmune drug cuts breast cancer progression risk in study
Positive Sentiment: BMY expanded its multi-year collaboration with Tempus AI, licensing multimodal oncology data through 2031 to aid target discovery and drug development. Separately, BMS is collaborating with Pathos AI and Tempus on AI-driven research in Alzheimer’s disease and other neurological conditions, while leading Pathos’s Series E financing and gaining access to its Foundry platform. These deals may improve research productivity and pipeline potential, although financial benefits are longer term. Tempus Expands Strategic Collaboration with Bristol Myers Squibb Pathos AI Announces Strategic Collaborations
Positive Sentiment: Analyst H. Engel modestly raised Erste Group’s FY2027 EPS forecast to $6.56 from $6.53, matching consensus and suggesting stable expectations for BMY’s earnings power. Bristol Myers Squibb analyst estimate update
Neutral Sentiment: Phase 1 Breakfree-2 data for the CAR-T therapy zolacabtagene autoleucel in highly active multiple sclerosis provide another pipeline catalyst, but the early-stage study still requires larger and later-stage testing before its commercial value can be assessed. Bristol Myers Squibb Presents Breakfree-2 Results
Negative Sentiment: Bristol Myers disclosed a patient death in the early-stage cell-therapy study. Even if the event does not ultimately change the program’s development, it introduces a safety overhang and may overshadow the positive efficacy data. Bristol Myers discloses patient death in early-stage cell therapy study
Negative Sentiment: Pre-earnings coverage anticipates a year-over-year decline in third-quarter earnings, keeping attention on legacy-drug erosion, pipeline execution and BMY’s relatively high debt load. These concerns could outweigh the company’s inexpensive valuation and attractive dividend in the near term. Earnings Preview: Bristol Myers Squibb Q3 Earnings Expected to Decline

Bristol Myers Squibb Company Profile

(Get Free Report)

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.

Analyst Recommendations for Bristol Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.